

## Technology Advisory Interests Register

**Topic: Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over  
[ID6457]**

**Publication Date: TBC**

| Name               | Role with NICE       | Type of interest           | Description of interest  | Interest declared | Comments  |
|--------------------|----------------------|----------------------------|--|-------------------|---|
| Elizabeth Thurgar  | TAC Committee Member | Financial                  | I am currently working with Takeda (listed Comparator company) in unrelated indications, 1) central disorders of hypersomnolence 2) polycythaemia vera   | 09/03/2026        | It was agreed that Elizabeth's declaration would not prevent them from participating in discussions on this appraisal |
| Clare Offer        | TAC Committee Member | Non-financial professional | I am the public health representative on the NHSE Clinical Reference Group for Allergy and Immunology as part of my day job with NHS England. I do not receive any additional payment for this and I have not had any direct involvement with or been consulted about the submission for Donidalorsen. | 12/03/2026        | It was agreed that Clare's declaration would not prevent them from participating in discussions on this appraisal     |
| Satish Venkateshan | TAC Committee Member | Financial                  | Regeneron is developing REGN9533 targeting factor XII and in collaboration with Alynlam developing ALN-F1202 targeting factor XII. I work for Regeneron, pharmaceuticals/biotech company. I  | 16/03/2026        | It was agreed that Satish's declaration would prevent them from participating in discussions on this appraisal        |

| Name            | Role with NICE | Type of interest   | Description of interest   | Interest declared | Comments  |
|-----------------|----------------|--------------------|---|-------------------|---|
|                 |                |                    | also own shares in the company and have stock options.  |                   |   |
| Angela Metcalfe | Expert         | Financial          | Unrestricted grants in the financial year ended September 2024 (last audited accounts) to HAE UK<br>BioCryst Pharmaceuticals £20,150  | 29/10/2025        | It was agreed that Angela's declaration would not prevent them from providing expert advice to the committee  |
| Dr Anthony Dorr | Expert         | Direct - financial | <ul style="list-style-type: none"> <li>• Takeda pharmaceutical: Promotional immunology exchange 26-27/09/2024 – £1387.50</li> <li>• Takeda pharmaceutical – talking head video at promotional immunology exchange 27/09/2024 - £185</li> <li>• BioCryst BSI-CIPN sponsored promotional; symposium speaker 09/12/2024 - £2014</li> <li>• BioCryst Advisory Board: 18/03/2025 - £848</li> <li>• Otsuka pharmaceutical: Paid work for donidalorsen advisory board 01/05/2025 - £720</li> <li>• CSL Behring: EAACI sponsored promotional symposium speaker 14/06/2025- £2008</li> </ul> | 30/10/2025        | It was agreed that Dr Dorr's declaration would not prevent them from providing expert advice to the committee |

| Name | Role with NICE | Type of interest       | Description of interest   | Interest declared | Comments |
|------|----------------|------------------------|---|-------------------|----------|
|      |                |                        | <ul style="list-style-type: none"> <li>• Takeda pharmaceutical: Promotional webinar for Takhyro 04/07/2025 - £1102.50</li> <li>• Takeda pharmaceutical: Health Care Professional Council 23/09/2025. Nil payment so far – on-going</li> <li>• Otsuka pharmaceutical: Paid work for input in validation of health technology assessment (HTA) materials for donidalorsen June and September 2025. On-going.</li> </ul>                                 |                   |          |
|      |                | Direct – non-financial | <ul style="list-style-type: none"> <li>• BioCryst: Sponsorship to attend BSI-CIPN 09-10/12/2024.</li> <li>• BioCryst: Sponsorship to attend AAAAI 28/02/2025-03/03/2025.</li> <li>• CSL Behring: Sponsorship to attend EAACI 2025</li> <li>• Sub-investigator in Ionis CS7 trial 03/08/2022-present</li> <li>• Have made commentary on newly approved treatment (garadacimab) for CSL Behring via press release 23/09/2025 and 30/01/2025.</li> </ul> |                   |          |